about
Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced DyskinesiaPatient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate modelsStem cell-based approach for the treatment of Parkinson's diseaseTransplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian modelsNeuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson diseaseClonal human fetal ventral mesencephalic dopaminergic neuron precursors for cell therapy researchBDNF increases survival and neuronal differentiation of human neural precursor cells cotransplanted with a nanofiber gel to the auditory nerve in a rat model of neuronal damage.Remote control of induced dopaminergic neurons in parkinsonian rats.Converted neural cells: induced to a cure?Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem CellsGeneration of induced neurons via direct conversion in vivo.Neuroligin-1 overexpression in newborn granule cells in vivo.Optimization of the magnetic labeling of human neural stem cells and MRI visualization in the hemiparkinsonian rat brainDiffusion tensor imaging of the nigrostriatal fibers in Parkinson's diseaseBee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.A brief history of triplet repeat diseases.Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking.Intracerebral transplantation for neurological disorders. Lessons from developmental, experimental, and clinical studies.Cell replacement and visual restoration by retinal sheet transplantsDopaminergic axon guidance: which makes what?Cellular programming and reprogramming: sculpting cell fate for the production of dopamine neurons for cell therapy.Adult subventricular zone neural stem cells as a potential source of dopaminergic replacement neuronsDyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Modeling physiological and pathological human neurogenesis in the dish.Short-Term Grafting of Human Neural Stem Cells: Electrophysiological Properties and Motor Behavioral Amelioration in Experimental Parkinsons Disease.Growing neural stem cells from conventional and nonconventional regions of the adult rodent brain.The proteome of the differentiating mesencephalic progenitor cell line CSM14.1 in vitro.Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate.Stem cells as in vitro model of Parkinson's disease.Restoration of the striatal circuitry: from developmental aspects toward clinical applications.Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.Nuclear receptors: Oxysterols detour to neurodevelopment.Defined Culture Conditions Accelerate Small-molecule-assisted Neural Induction for the Production of Neural Progenitors from Human-induced Pluripotent Stem Cells.Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells.Regulating Wnt signaling: a strategy to prevent neurodegeneration and induce regeneration.Neuroimaging for optimization of stem cell therapy in Parkinson's disease.Phenotypic Reprogramming of Striatal Neurons into Dopaminergic Neuron-like Cells in the Adult Mouse Brain
P2860
Q26765499-63249A15-ECF5-48BD-9BB1-7BA77B526E80Q26825524-08547EBC-13C8-41C9-A8EA-503EF9979030Q27004330-0F509E1E-51B6-4663-A7F7-5D4AA85F187EQ27315880-C46D85A2-41E6-4187-9EE1-46663D968F90Q28259054-DAD8E205-9963-44A1-9669-24F5748CA78EQ28484677-E9348474-6887-4324-A7EB-EED4ABC4E795Q30430529-EFE891D8-CF20-4C0A-8D27-80E08495FE0EQ30581671-9B3E9C83-A9D7-41CA-821C-0B7BB70D0CC4Q33924616-7F01C6B0-0C15-4DDC-A3FF-514C1A88653FQ34109406-B6CAF82E-FCE2-4A22-8D30-48836D15039CQ34335374-2BF857AC-FDD8-4186-9F07-B377EA595210Q34460907-8C424B1A-05D3-442E-8427-1AF375CFA176Q35559206-34A1D1FF-33AC-47A5-A4DF-FB4B9A7FEB78Q35564787-CB318266-1303-4D5F-A871-3B369D73133EQ35842101-70405E2C-F55E-499F-9627-78ACFB05E81AQ36410154-494E6B97-DD87-4EE7-ACF9-7AAA1009D98AQ37553564-21ABA776-AAB3-4872-A82A-4A8845D3D937Q37643268-0D088618-D964-4F1B-B4AB-098D9824576EQ37982705-2209DBB5-6671-47A4-9622-501613F7E2ACQ38024553-71CF7A9F-217E-4F2C-953A-2260B7BBD0EAQ38032274-3F001B75-B22C-42E8-9DD7-2EC64FCC8994Q38044388-93150A52-361C-4AB8-8B5D-952A90916EAAQ38191589-127AE205-78E4-4358-9C87-51EF11A83ACEQ38207680-594814F8-4CB1-4105-A2C6-9E908BA595BDQ38238081-073B991A-D01E-49D0-94B7-AF1EED62318AQ38763195-09F58A04-1168-4451-BB76-E49D1E178B06Q38823353-B42122ED-2BBB-483C-89BF-CB031E4F2502Q39018803-FABB82B3-07A0-4B02-B40F-4663EFCA69DAQ42072961-C04F0E33-2ADC-4690-BEEB-46B7EFE7E6B3Q42159528-18D799A5-1C72-425E-A869-8FD0C9525A1DQ42505344-C78113AB-B10E-4E08-A0A5-574CD7E1E81DQ45873810-5C856F32-B961-4E9B-882D-92BB9DE2D2E7Q46012170-07E9A557-6102-4F4F-818E-64FA8B63EE04Q47698746-73EEFFC6-F81E-4CD8-B0FE-AD0708CB3CA6Q47729890-C7A4C250-A654-4AFE-B4D9-667DA694307CQ51752619-055F19A5-86CC-46BA-98B8-D1099E9DC519Q54637329-24FF7315-6A44-475C-ABF5-B9F325FE7336Q57490619-2A1EE0E8-F695-4C5B-8CDD-9AB06FDDAFE6
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cell therapeutics in Parkinson's disease.
@en
Cell therapeutics in Parkinson's disease.
@nl
type
label
Cell therapeutics in Parkinson's disease.
@en
Cell therapeutics in Parkinson's disease.
@nl
prefLabel
Cell therapeutics in Parkinson's disease.
@en
Cell therapeutics in Parkinson's disease.
@nl
P2860
P1433
P1476
Cell therapeutics in Parkinson's disease.
@en
P2093
Olle Lindvall
P2860
P2888
P304
P356
10.1007/S13311-011-0069-6
P577
2011-10-01T00:00:00Z